Low-dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicity
- 1 August 1994
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 39 (8), 1638-1641
- https://doi.org/10.1007/bf02087769
Abstract
A feared complication of therapy with 6-mercaptopurine (6-MP) is myelosuppression. To evaluate whether rigorous blood count monitoring is necessary, we prospectively followed the hematologic profiles of 57 patients with inflammatory bowel disease who were treated with low-dose 6-MP. Most patients (97%) were treated initially with a single dose of 50 mg/day and 79% never used more than 50 mg/day. Blood counts were obtained at weekly intervals over the first month, every two weeks for the second month, and monthly thereafter in the first year. Sixteen (28%) developed mild leukopenia (white blood count 3/mm3). No patient had a white blood cell count 3/mm3 and no patient developed leukopenia prior to three months of treatment. In only five patients did the leukopenia prompt a change in 6-mercaptopurine dose. Very mild thrombocytopenia (platelet count of 101 fl) was seen in nine (16%). In conclusion, leukopenia was not uncommon in patients treated with low-dose 6-MP, but was not clinically significant. Leukopenia occurred no earlier than three months and as late as 42 months into therapy. Thrombocytopenia was uncommon, mild, and was not associated with apparent bleeding. Macrocytosis may occur in the absence of vitamin B12 and folate deficiencies. Patients can be spared from weekly blood count monitoring when using low-dose 6-mercaptopurine treatment.Keywords
This publication has 15 references indexed in Scilit:
- Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience.Gut, 1993
- Randomised controlled trial of azathioprine withdrawal in ulcerative colitis.BMJ, 1992
- Azathioprine in myasthenia gravis: Observations in 41 patients and a review of literatureNeuromuscular Disorders, 1991
- Azathioprine in dermatologyJournal of the American Academy of Dermatology, 1991
- Thiopurine pharmacogenetics in leukemia: Correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrationsClinical Pharmacology & Therapeutics, 1987
- Severe megaloblastic anaemia associated with abnormal azathioprine metabolism.British Journal of Clinical Pharmacology, 1984
- Thiopurine methyltransferase biochemical genetics: Human lymphocyte activityBiochemical Genetics, 1982
- Treatment of Crohn's Disease with 6-MercaptopurineNew England Journal of Medicine, 1980
- OBSERVATIONS ON THE INCIDENCE AND CAUSE OF MACROCYTOSIS IN PATIENTS ON AZATHIOPRINE THERAPY FOLLOWING RENAL TRANSPLANTATIONTransplantation, 1974
- CONTROLLED TRIAL OF AZATHIOPRINE IN CROHN'S DISEASEThe Lancet, 1971